Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins

More than one and half years have passed, as of August 2021, since the COVID-19 caused by the novel coronavirus named SARS-CoV-2 emerged in 2019. While the recent success of vaccine developments likely reduces the severe cases, there is still a strong requirement of safety and effective therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hijikata, Atsushi, Shionyu, Clara, Nakae, Setsu, Shionyu, Masafumi, Ota, Motonori, Kanaya, Shigehiko, Shirai, Tsuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Biophysical Society of Japan 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550875/
https://www.ncbi.nlm.nih.gov/pubmed/34745807
http://dx.doi.org/10.2142/biophysico.bppb-v18.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8550875/
https://www.ncbi.nlm.nih.gov/pubmed/34745807
http://dx.doi.org/10.2142/biophysico.bppb-v18.025

Ejemplares similares